Want to see GB:EAH full AI Analyst Report?
EAH Stock Chart & Stats
78.50 p
0.39 p(0.55%)
At close: 4:00 PM EST
78.50 p
0.39 p(0.55%)
Day’s Range― - ―
52-Week Range55.56 p - 116.90 p
Previous CloseN/A
Volume691.00
Average Volume (3M)75.04K
Market Cap
£64.71M
Enterprise Value48.43M
Total Cash (Recent Filing)£18.64M
Total Debt (Recent Filing)£5.06M
Price to Earnings (P/E)21.4
Beta0.61
Next Earnings
Jul 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding67,759,674
10 Day Avg. Volume57,390
30 Day Avg. Volume75,042
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)0.42
Price to Sales (P/S)0.45
P/FCF Ratio6.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)£88.76M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageA conservative leverage profile and healthy equity ratio provide long-term financial flexibility to fund registrations, geographic expansion, and R&D without relying heavily on external debt. This supports sustained operations across multi-year product approval cycles and volatility in livestock markets.
Improving Free Cash Flow GenerationRising free cash flow strengthens the company’s ability to reinvest in commercialization, regulatory filings, and targeted acquisitions. Steady FCF reduces dependence on capital markets and enables predictable funding for product rollout across multiple geographies over the next several quarters.
Commercial Model & Regulatory-enabled Product SalesA hybrid go-to-market—direct subsidiaries plus third-party partners—combined with proprietary products and country-by-country regulatory registrations creates durable revenue channels. This diversified commercial footprint mitigates single-market risk and supports gradual, sustainable revenue expansion.
Bears Say
Inconsistent Revenue GrowthIrregular top-line performance undermines predictability of cash flows and complicates investment planning. For a company relying on regulatory approvals and phased product rollouts, uneven revenue suggests commercial execution or market adoption issues that could persist over multiple reporting periods.
Low And Declining MarginsEroding gross margins and low net margins constrain the ability to fund R&D and expand commercial infrastructure from operating profits. Persistent margin pressure reduces resilience to input cost shocks and limits ability to scale profitably across new markets over the medium term.
Operating Cash Conversion Below EarningsWeaker conversion of reported earnings into cash raises concerns about working capital and the sustainability of reported profits. If recurring, this gap can limit capacity to self-fund regulatory submissions and commercial expansion, forcing dependence on external capital over multiple quarters.
Eco Animal Health News
EAH FAQ
What was Eco Animal Health Group PLC’s price range in the past 12 months?
Eco Animal Health Group PLC lowest share price was 55.55 p and its highest was 116.90 p in the past 12 months.
What is Eco Animal Health Group PLC’s market cap?
Eco Animal Health Group PLC’s market cap is £64.71M.
When is Eco Animal Health Group PLC’s upcoming earnings report date?
Eco Animal Health Group PLC’s upcoming earnings report date is Jul 20, 2026 which is in 15 days.
How were Eco Animal Health Group PLC’s earnings last quarter?
Eco Animal Health Group PLC released its earnings results on Dec 01, 2025. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005 p.
Is Eco Animal Health Group PLC overvalued?
According to Wall Street analysts Eco Animal Health Group PLC’s price is currently Overvalued.
Does Eco Animal Health Group PLC pay dividends?
Eco Animal Health Group PLC pays a Annually dividend of 1 p which represents an annual dividend yield of N/A. See more information on Eco Animal Health Group PLC dividends here
What is Eco Animal Health Group PLC’s EPS estimate?
Eco Animal Health Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eco Animal Health Group PLC have?
Eco Animal Health Group PLC has 67,759,674 shares outstanding.
What happened to Eco Animal Health Group PLC’s price movement after its last earnings report?
Eco Animal Health Group PLC reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.255%.
Which hedge fund is a major shareholder of Eco Animal Health Group PLC?
Currently, no hedge funds are holding shares in GB:EAH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eco Animal Health Stock Smart Score
Company Description
Eco Animal Health Group PLC
ECO Animal Health Group plc, established in 1972 and based in New Malden, United Kingdom, focuses on the worldwide research, regulatory approval, and distribution of veterinary pharmaceutical solutions. The company's offerings include Aivlosin, a macrolide antibiotic specifically formulated to address digestive and respiratory illnesses in pigs and poultry. Additionally, its product range encompasses various generic drugs like Ecomectin, Ecoheart, Ecotraz, and Ecomintic. These endectocides and other antiparasitics are designed to manage and prevent parasitic infestations such as worms, ticks, and lice across a diverse array of animals, including cattle, sheep, pigs, horses, and dogs. ECO Animal Health Group also provides Chlortetracycline and Oxytetracycline for treating bacterial infections in swine, fowl, and bovine animals.
Technical Analysis
Options Prices
Currently, No data available
---